Investor Belanoff Joseph K
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Belanoff Joseph K . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-02-14 13G/A CORT / Corcept Therapeutics Incorporated 6,581,918 6,822,335
2024-02-12 13G/A CORT / Corcept Therapeutics Incorporated 6,081,918 6,581,918
2023-02-15 13G/A CORT / Corcept Therapeutics Incorporated 6,374,376 6,081,918
2022-02-11 13G/A CORT / Corcept Therapeutics Incorporated 6,367,964 6,374,376
2021-02-11 13G CORT / Corcept Therapeutics Incorporated 5,377,736 6,367,964
2017-01-24 13G/A CORT / Corcept Therapeutics Incorporated 5,377,736
2015-02-13 13G/A CORT / Corcept Therapeutics Incorporated 5,930,887
2014-02-11 13G/A CORT / Corcept Therapeutics Incorporated 5,530,879
2013-02-14 13G/A CORT / Corcept Therapeutics Incorporated 5,103,805
2012-02-14 13G/A CORT / Corcept Therapeutics Incorporated 4,278,794